ClinicalTrials.gg

TargetBeta

FOLH1

folate hydrolase 1 · also PSM, PSMA, NAALAD1, NAALAdase · M28 metallopeptidases

22 programs in company-led studies act on FOLH1, from 16 companies: 7 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
piflufolastatruleLantheusphase 451 running–NCIt
flotufolastat F 18ruleBraccophase 470 running–the studies' text
abefolastat tesaroxetan CU-64ruleClarity Pharmaceuticalsphase 353 running–NCIt
gallium 68 PSMA-11ruleNovartisphase 343 running–NCIt
Lutetium Lu 177 LudotadipepruleFutureChemphase 332 running–NCIt
actinium AC-225 vipivotide tetraxetanNovartisphase 322 running–the company's pipeline
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 322 runningCD28a judged reading
HRS-4357Jiangsu HengRui Medicinephase 322 running–the company's pipeline
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 322 running–NCIt
zadavotide guraxetanAstraZenecaphase 244 running–a judged reading
olsutamigruleRegeneron Pharmaceuticalsphase 222 runningCD3ENCIt
SHR-4394Jiangsu HengRui Medicinephase 222 running–the company's pipeline
AB-001ruleFrontier Biotechnologiesphase 231 running–the studies' text
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505ruleRegeneron Pharmaceuticalsphase 211 runningTNFRSF9NCIt
Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514ruleGlaxoSmithKlinephase 211 runningCD3ENCIt
HRS-1738Jiangsu HengRui Medicinephase 211 running–the company's pipeline
TD001ruleT.O.A.D. Oncologyphase 211 running–the studies' text
Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028ruleArsenal Biosciencesphase 210 runningFAS, TGFB1, TGFBR2NCIt
Anti-PSMA Antibody-drug Conjugate ARX517Johnson & Johnsonphase 122 running–a judged reading
Anti-PSMA/CD3 Protease-activated T-cell Engager JANX007ruleJanux Therapeuticsphase 122 running–NCIt
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014ruleJanux Therapeuticsphase 111 runningCD3ENCIt
Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969AbbViephase 111 runningSTEAP1the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.